US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

3.645 +0.115 (+3.26%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study ↗
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary... 
Via Benzinga
News headline image
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
News headline image
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >